Topline results from the Phase III SURPASS-1 trial show that a 40-week treatment with Eli Lilly's tirzepatide led to significant reductions in A1c and body weight in adults with type 2 diabetes.

https://www.biospace.com/article/late-stage-trial-results-show-promise-for-eli-lilly-s-tirzepatide-as-treatment-for-type-2-diabetes/